Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 5/20 | 0.31 |
| ▸ | PRKCA | P17252 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8672226 | 0.89 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL1225013 | 0.87 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL332045 | 0.85 | ATM (0.48) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL26094895 | 0.84 | ATM (0.44) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL3304908 | 0.84 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL10398160 | 0.84 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL932962 | 0.84 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL12095075 | 0.83 | ATM (0.50) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL26095997 | 0.83 | HCAR2 (0.44) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL26095195 | 0.83 | HCAR2 (0.44) | ATMHCAR2MAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2930177-B1 | PREPARATION OF SILAZANE COMPOUND | SHINETSU CHEMICAL CO (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9416147-B2 | Preparation of silazane compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-16 | — | — | US | disclosed |
| EP-2930177-A1 | Preparation of silazane compound | Shin-Etsu Chemical Co., Ltd. (JP) | 2015-10-14 | — | — | EP | disclosed |
| US-20150284414-A1 | PREPARATION OF SILAZANE COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284414-A1 | PREPARATION OF SILAZANE COMPOUND | SLTM, SKP2, BCAT2 | ATM 409/4885HCAR2 3706/4885MAPT 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.